@kolpulseai.bsky.social
Reposted
Winship CMO and #multiplemyeloma expert Sagar Lonial, MD, stopped by our booth to let us know what he is looking forward to at this year’s #ASCO25.
May 31, 2025 at 8:09 PM
Winship CMO and #multiplemyeloma expert Sagar Lonial, MD, stopped by our booth to let us know what he is looking forward to at this year’s #ASCO25.
Reposted
Patients > Profits
THIS abstract at #ASCO25 gives me so much hope!!
Way to go @thewonkologist.bsky.social @ascocancer.bsky.social 👊🏽
THIS abstract at #ASCO25 gives me so much hope!!
Way to go @thewonkologist.bsky.social @ascocancer.bsky.social 👊🏽
Presenting at #ASCO25 today!
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
June 1, 2025 at 1:49 PM
Patients > Profits
THIS abstract at #ASCO25 gives me so much hope!!
Way to go @thewonkologist.bsky.social @ascocancer.bsky.social 👊🏽
THIS abstract at #ASCO25 gives me so much hope!!
Way to go @thewonkologist.bsky.social @ascocancer.bsky.social 👊🏽
Reposted
Progression-free survival is NOT an ideal endpoint (advocates could have told you this!)
Interesting to see the intentions behind it as an endpoint tho
#ASCO25
~ Chris Booth
Interesting to see the intentions behind it as an endpoint tho
#ASCO25
~ Chris Booth
May 30, 2025 at 6:35 PM
Progression-free survival is NOT an ideal endpoint (advocates could have told you this!)
Interesting to see the intentions behind it as an endpoint tho
#ASCO25
~ Chris Booth
Interesting to see the intentions behind it as an endpoint tho
#ASCO25
~ Chris Booth
Reposted
Presenting at #ASCO25 today!
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
May 31, 2025 at 9:25 PM
Presenting at #ASCO25 today!
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not.
Cc @dusetzinas.bsky.social
Reposted
Watch as Prof. Ola Landgren shares his excitement about the upcoming Miami Myeloma MRD Meeting 2025!🩸
🎥 https://buff.ly/41v8Cob
Want updates on all things #MRD in #MultipleMyeloma?
REGISTER for the hybrid event here:
👉 https://buff.ly/437WXx3 👈
#MMSM #mmMRD #Myeloma #HemeOnc #BloodSky #HemeSky
🎥 https://buff.ly/41v8Cob
Want updates on all things #MRD in #MultipleMyeloma?
REGISTER for the hybrid event here:
👉 https://buff.ly/437WXx3 👈
#MMSM #mmMRD #Myeloma #HemeOnc #BloodSky #HemeSky
February 27, 2025 at 9:32 AM
Watch as Prof. Ola Landgren shares his excitement about the upcoming Miami Myeloma MRD Meeting 2025!🩸
🎥 https://buff.ly/41v8Cob
Want updates on all things #MRD in #MultipleMyeloma?
REGISTER for the hybrid event here:
👉 https://buff.ly/437WXx3 👈
#MMSM #mmMRD #Myeloma #HemeOnc #BloodSky #HemeSky
🎥 https://buff.ly/41v8Cob
Want updates on all things #MRD in #MultipleMyeloma?
REGISTER for the hybrid event here:
👉 https://buff.ly/437WXx3 👈
#MMSM #mmMRD #Myeloma #HemeOnc #BloodSky #HemeSky
Reposted
This is good progress
We need effective TKIs for EGFR Ex20 Ins disease
Sunvozertinib licensed and routinely used in China, but not yet in Europe or USA
Likely to have less skin, but more GI, toxicity than Amivantamab
We need effective TKIs for EGFR Ex20 Ins disease
Sunvozertinib licensed and routinely used in China, but not yet in Europe or USA
Likely to have less skin, but more GI, toxicity than Amivantamab
The FDA granted priority review to the NDA for sunvozertinib for patients with locally advanced or metastatic #NSCLC with exon20ins, as identified by an #FDA-approved test, who have experienced disease progression after platinum-based chemotherapy. #lcsm
www.targetedonc.com/view/fda-gra...
www.targetedonc.com/view/fda-gra...
FDA Grants Priority Review to Sunvozertinib in EGFR+ NSCLC
The FDA granted priority review to sunvozertinib for the treatment of advanced NSCLC with EGFR exon 20 mutations, based on promising efficacy and safety data from the WU-KONG1 trial.
www.targetedonc.com
January 11, 2025 at 12:41 PM
This is good progress
We need effective TKIs for EGFR Ex20 Ins disease
Sunvozertinib licensed and routinely used in China, but not yet in Europe or USA
Likely to have less skin, but more GI, toxicity than Amivantamab
We need effective TKIs for EGFR Ex20 Ins disease
Sunvozertinib licensed and routinely used in China, but not yet in Europe or USA
Likely to have less skin, but more GI, toxicity than Amivantamab
Reposted
Anito-cel vs. CARVYKTI: The next big BCMA CAR-T rivalry? 🚨
With strong efficacy, cleaner safety, and Kite's manufacturing edge, can anito-cel disrupt CARVYKTI's dominance?
#ASH2024 #BCMACART #MultipleMyeloma
Full post here: bigpharmasharma.substack.com/p/ash-part-2...
With strong efficacy, cleaner safety, and Kite's manufacturing edge, can anito-cel disrupt CARVYKTI's dominance?
#ASH2024 #BCMACART #MultipleMyeloma
Full post here: bigpharmasharma.substack.com/p/ash-part-2...
ASH Part 2: Anito-cel is off to the races, but will it be fast enough to catch-up to Cilta-cel?
Arcellx presented Phase 2 pivotal iMMagine-1 data for anito-cel, their BCMA-targeted CAR-T for 5L+ relapsed/refractory multiple myeloma (RRMM), at ASH 2024.
bigpharmasharma.substack.com
December 11, 2024 at 7:24 PM
Anito-cel vs. CARVYKTI: The next big BCMA CAR-T rivalry? 🚨
With strong efficacy, cleaner safety, and Kite's manufacturing edge, can anito-cel disrupt CARVYKTI's dominance?
#ASH2024 #BCMACART #MultipleMyeloma
Full post here: bigpharmasharma.substack.com/p/ash-part-2...
With strong efficacy, cleaner safety, and Kite's manufacturing edge, can anito-cel disrupt CARVYKTI's dominance?
#ASH2024 #BCMACART #MultipleMyeloma
Full post here: bigpharmasharma.substack.com/p/ash-part-2...
Reposted
In this phase 3 trial, researchers evaluated the addition of the bispecific T-cell engager blinatumomab to standard chemotherapy in children with newly diagnosed standard-risk B-cell acute lymphoblastic leukemia (B-cell ALL) at average or high risk of relapse.
https://buff.ly/3ZuugqE
https://buff.ly/3ZuugqE
December 9, 2024 at 8:58 PM
Reposted
Welcome to this OncoAlert Session Round Up during #ASH24, focusing on #MultipleMyeloma pharmacologic therapie
✅ GMMG-HD7 (JCO Publication)
https://buff.ly/4g4llTX
✅ IMROZ Trial (Phase 3)
✅ UK MRA Myeloma XI+ Trial
✅ DREAMM-7 Trial (Phase 3)
✅ AQUILA (NEJM Publication)
https://buff.ly/4fcbHgK
✅ GMMG-HD7 (JCO Publication)
https://buff.ly/4g4llTX
✅ IMROZ Trial (Phase 3)
✅ UK MRA Myeloma XI+ Trial
✅ DREAMM-7 Trial (Phase 3)
✅ AQUILA (NEJM Publication)
https://buff.ly/4fcbHgK
OncoAlert Session Round Up at ASH 24 in Multiple Myeloma: pharmacologic Therapies: Refining Evidence
Welcome to this OncoAlert Session Round Up during ASH24, focusing on Multiple Myeloma pharmacologic therapies.GMMG-HD7 Trial (JCO Publication)This phase 3 tr...
buff.ly
December 9, 2024 at 10:11 PM
Welcome to this OncoAlert Session Round Up during #ASH24, focusing on #MultipleMyeloma pharmacologic therapie
✅ GMMG-HD7 (JCO Publication)
https://buff.ly/4g4llTX
✅ IMROZ Trial (Phase 3)
✅ UK MRA Myeloma XI+ Trial
✅ DREAMM-7 Trial (Phase 3)
✅ AQUILA (NEJM Publication)
https://buff.ly/4fcbHgK
✅ GMMG-HD7 (JCO Publication)
https://buff.ly/4g4llTX
✅ IMROZ Trial (Phase 3)
✅ UK MRA Myeloma XI+ Trial
✅ DREAMM-7 Trial (Phase 3)
✅ AQUILA (NEJM Publication)
https://buff.ly/4fcbHgK
Reposted
Welcome to this OncoAlert Session Round Up during #ASH24, focusing on #MultipleMyeloma pharmacologic therapie
✅ GMMG-HD7 (JCO Publication)
https://buff.ly/4g4llTX
✅ IMROZ Trial (Phase 3)
✅ UK MRA Myeloma XI+ Trial
✅ DREAMM-7 Trial (Phase 3)
✅ AQUILA (NEJM Publication)
https://buff.ly/4fcbHgK
✅ GMMG-HD7 (JCO Publication)
https://buff.ly/4g4llTX
✅ IMROZ Trial (Phase 3)
✅ UK MRA Myeloma XI+ Trial
✅ DREAMM-7 Trial (Phase 3)
✅ AQUILA (NEJM Publication)
https://buff.ly/4fcbHgK
OncoAlert Session Round Up at ASH 24 in Multiple Myeloma: pharmacologic Therapies: Refining Evidence
Welcome to this OncoAlert Session Round Up during ASH24, focusing on Multiple Myeloma pharmacologic therapies.GMMG-HD7 Trial (JCO Publication)This phase 3 tr...
buff.ly
December 9, 2024 at 10:15 PM
Reposted
There’s also a directory of starter packs - blueskydirectory.com/starter-pack...
There’s myeloma and amyloid enthusiasts for sure in there?
There’s myeloma and amyloid enthusiasts for sure in there?
Bluesky Starter Packs - Bluesky Directory
Browse a list of Bluesky Starter Packs. Discover and connect with your community on Bluesky
blueskydirectory.com
December 10, 2024 at 1:41 AM
There’s also a directory of starter packs - blueskydirectory.com/starter-pack...
There’s myeloma and amyloid enthusiasts for sure in there?
There’s myeloma and amyloid enthusiasts for sure in there?
Reposted
Tweetorial: AA amyloidosis and Cancer - New article of analysis in the literature by our #glomerular center visiting faculty @Joyita_4 along with @MSK_Neph faculty @DrOscarLahoud...
December 10, 2024 at 12:12 PM
Tweetorial: AA amyloidosis and Cancer - New article of analysis in the literature by our #glomerular center visiting faculty @Joyita_4 along with @MSK_Neph faculty @DrOscarLahoud...
Reposted
Exciting insights from Day 2 of #ASH2024! From promising results on the use of Tecvayli in combination with other drugs to advances in bispecific antibody treatments, these breakthroughs are potentially shaping the future of myeloma care. Read the highlights: 👉 themmrf.org/mmrf-blogs/m...
MMRF ASH 2024 Blog: Day 2 - MMRF
Welcome to the second day of our recap of the latest findings on myeloma treatments reported at the American Society of Hematology (ASH) meeting in San Diego. Highlights from today included: Promising...
themmrf.org
December 10, 2024 at 2:30 PM
Exciting insights from Day 2 of #ASH2024! From promising results on the use of Tecvayli in combination with other drugs to advances in bispecific antibody treatments, these breakthroughs are potentially shaping the future of myeloma care. Read the highlights: 👉 themmrf.org/mmrf-blogs/m...
Reposted
These findings underscore the PFS benefit of Isa-RVd, even without consolidation therapy, across maintenance strategies.
#MultipleMyeloma #ASH24
#MultipleMyeloma #ASH24
JUST OUT #ASH24
GMMG-HD7 trial evaluated the addition of isatuximab to the standard lenalidomide-bortezomib-dexamethasone regimen in transplant-eligible patients with newly diagnosed multiple myeloma. Underscore the PFS benefit of Isa-RVd, even without consolidation therapy
https://buff.ly/4g4llTX
GMMG-HD7 trial evaluated the addition of isatuximab to the standard lenalidomide-bortezomib-dexamethasone regimen in transplant-eligible patients with newly diagnosed multiple myeloma. Underscore the PFS benefit of Isa-RVd, even without consolidation therapy
https://buff.ly/4g4llTX
December 9, 2024 at 9:00 PM
These findings underscore the PFS benefit of Isa-RVd, even without consolidation therapy, across maintenance strategies.
#MultipleMyeloma #ASH24
#MultipleMyeloma #ASH24
Reposted
Presented at #ASH24:
Among patients with smoldering multiple myeloma at a high risk for progression, progression-free survival at 5 years was 63.1% with daratumumab monotherapy, as compared with 40.8% with active monitoring. Full AQUILA trial results: nej.md/3Zh3pOJ
#MedSky
Among patients with smoldering multiple myeloma at a high risk for progression, progression-free survival at 5 years was 63.1% with daratumumab monotherapy, as compared with 40.8% with active monitoring. Full AQUILA trial results: nej.md/3Zh3pOJ
#MedSky
December 9, 2024 at 9:00 PM
Presented at #ASH24:
Among patients with smoldering multiple myeloma at a high risk for progression, progression-free survival at 5 years was 63.1% with daratumumab monotherapy, as compared with 40.8% with active monitoring. Full AQUILA trial results: nej.md/3Zh3pOJ
#MedSky
Among patients with smoldering multiple myeloma at a high risk for progression, progression-free survival at 5 years was 63.1% with daratumumab monotherapy, as compared with 40.8% with active monitoring. Full AQUILA trial results: nej.md/3Zh3pOJ
#MedSky
Reposted
🚨 GSK’s antibody-drug conjugate Blenrep ⬇️ risk of myeloma death by 42% compared with Darzalex in their respective combinations with bortezomib and dexamethasone (planned interim analysis of the phase 3 DREAMM-7 trial)
www.fiercepharma.com/pharma/survi...
www.fiercepharma.com/pharma/survi...
ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep
GSK’s antibody-drug conjugate Blenrep has mounted a sizable patient survival benefit among certain multiple myeloma patients in a head-to-head comparison against Johnson & Johnson’s industry-le | GSK’...
www.fiercepharma.com
December 9, 2024 at 10:12 PM
🚨 GSK’s antibody-drug conjugate Blenrep ⬇️ risk of myeloma death by 42% compared with Darzalex in their respective combinations with bortezomib and dexamethasone (planned interim analysis of the phase 3 DREAMM-7 trial)
www.fiercepharma.com/pharma/survi...
www.fiercepharma.com/pharma/survi...
Reposted
Honorable mention #MajorPROsASH: real-world PROs w/ 1L dara
Like the trials, significant & sustained improvements in phys health (& anxiety/depression) with 1L dara-containing regimens. Further supports trial data (especially MAIA) showing improvements in QOL & pain. #ASH24 #mmsm
Like the trials, significant & sustained improvements in phys health (& anxiety/depression) with 1L dara-containing regimens. Further supports trial data (especially MAIA) showing improvements in QOL & pain. #ASH24 #mmsm
December 9, 2024 at 10:59 PM
Honorable mention #MajorPROsASH: real-world PROs w/ 1L dara
Like the trials, significant & sustained improvements in phys health (& anxiety/depression) with 1L dara-containing regimens. Further supports trial data (especially MAIA) showing improvements in QOL & pain. #ASH24 #mmsm
Like the trials, significant & sustained improvements in phys health (& anxiety/depression) with 1L dara-containing regimens. Further supports trial data (especially MAIA) showing improvements in QOL & pain. #ASH24 #mmsm
Reposted
📢 Breaking news from #ASH24! Daratumumab vs. active monitoring in smoldering myeloma shows:
✅ Significantly delayed disease progression
✅ Improved survival
✅ Under FDA review for high-risk SMM
This could transform early myeloma treatment from "watch & wait" to active intervention! #MyelomaResearch
✅ Significantly delayed disease progression
✅ Improved survival
✅ Under FDA review for high-risk SMM
This could transform early myeloma treatment from "watch & wait" to active intervention! #MyelomaResearch
December 9, 2024 at 8:05 PM
📢 Breaking news from #ASH24! Daratumumab vs. active monitoring in smoldering myeloma shows:
✅ Significantly delayed disease progression
✅ Improved survival
✅ Under FDA review for high-risk SMM
This could transform early myeloma treatment from "watch & wait" to active intervention! #MyelomaResearch
✅ Significantly delayed disease progression
✅ Improved survival
✅ Under FDA review for high-risk SMM
This could transform early myeloma treatment from "watch & wait" to active intervention! #MyelomaResearch
Reposted
Any #myeloma or #mmsm or #nephrology or #hematology or #ASH24 “starter packs” of accounts to follow out there? Just signed up and looking for my peeps.
December 9, 2024 at 5:36 PM
Any #myeloma or #mmsm or #nephrology or #hematology or #ASH24 “starter packs” of accounts to follow out there? Just signed up and looking for my peeps.
Reposted
I’m not sure I’m done w X, but for now, I’m pretty “done” with X. Keeping it focused on myeloma, amyloidosis, hematology, and science here. Maybe comics, art, backpacking, and running. No politics. Will not abide random aggressive trolling. #mmsm #myeloma #amyloidosis
December 9, 2024 at 6:00 PM
I’m not sure I’m done w X, but for now, I’m pretty “done” with X. Keeping it focused on myeloma, amyloidosis, hematology, and science here. Maybe comics, art, backpacking, and running. No politics. Will not abide random aggressive trolling. #mmsm #myeloma #amyloidosis
Reposted
Be skeptical of pharma PRO work: claim in this DREAMM pooled analysis that "blurred vision had minor impacts" on QOL, but multiple associations with worse QOL (global health, role fxn) were significant and no minimally important difference was stipulated. #mmsm #MajorPROsASH
December 9, 2024 at 6:19 PM
Be skeptical of pharma PRO work: claim in this DREAMM pooled analysis that "blurred vision had minor impacts" on QOL, but multiple associations with worse QOL (global health, role fxn) were significant and no minimally important difference was stipulated. #mmsm #MajorPROsASH
Reposted
Can 24h urine be eliminated as part of IMWG response criteria in myeloma? Secondary analysis of STaMINA by @rahulbanerjeemd.bsky.social at #ASH24 showed that eliminating 24h urine resulted in changed response in 1% with no impact on PFS prediction at any response depth. #hemesky #oncsky #mmsm
December 7, 2024 at 6:45 PM
Can 24h urine be eliminated as part of IMWG response criteria in myeloma? Secondary analysis of STaMINA by @rahulbanerjeemd.bsky.social at #ASH24 showed that eliminating 24h urine resulted in changed response in 1% with no impact on PFS prediction at any response depth. #hemesky #oncsky #mmsm
Reposted
Honorable mention #MajorPROsASH: PROs MGUS & SMM #ASH24
- worse anxiety, depression, fatigue, insomnia compared to general population
- anxiety much worse in MGUS (approaching severe!)
- pts want tx that prevent progression to MM
Need to align research priorities with pts. #mmsm
- worse anxiety, depression, fatigue, insomnia compared to general population
- anxiety much worse in MGUS (approaching severe!)
- pts want tx that prevent progression to MM
Need to align research priorities with pts. #mmsm
December 7, 2024 at 9:32 PM
Honorable mention #MajorPROsASH: PROs MGUS & SMM #ASH24
- worse anxiety, depression, fatigue, insomnia compared to general population
- anxiety much worse in MGUS (approaching severe!)
- pts want tx that prevent progression to MM
Need to align research priorities with pts. #mmsm
- worse anxiety, depression, fatigue, insomnia compared to general population
- anxiety much worse in MGUS (approaching severe!)
- pts want tx that prevent progression to MM
Need to align research priorities with pts. #mmsm